logo
logo

Ku Leuven Spin-Off Astrivax Raises € 30 Million Seed Capital To Build Vaccine Platform

Ku Leuven Spin-Off Astrivax Raises € 30 Million Seed Capital To Build Vaccine Platform

08/25/22, 5:06 AM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/BE.svgleuven
Money raised
€30 million
Industry
biotechnology
Round Type
seed

Company Info

Company
AstriVax
Location
ambachtenlaan
leuven, flemish brabant, belgium
Additional Info
AstriVax is a privately held spin-off company from the KU Leuven, founded in 2022 based on vaccine technology developed at the Rega Institute. AstriVax is building a first in class Plug & Play vaccine platform with a patented DNA based technology that launches self-amplifying live attenuated viruses. The versatile technology of AstriVax can be used to develop a wide range of vaccines to prevent and treat infectious diseases. AstriVax aims to address major challenges in vaccinology by developing novel vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection against various viruses and other pathogens.

Related People